Allspring Global Investments
FULC icon

Allspring Global Investments’s Fulcrum Therapeutics FULC Stock Holding History

Allspring Global Investments’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,176
Closed -$74K – 2916
2022
Q3 		$74K Buy
+9,176
New +$65.7K ﹤0.01% 2194
2022
Q2 		– Sell
-5,277
Closed -$124K – 2773
2022
Q1 		$124K Sell
5,277
-595
-10% -$8.42K ﹤0.01% 2705
2021
Q4 		$103K Buy
+5,872
New +$116K ﹤0.01% 2763

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Allspring Global Investments's FULC Position: Q4 2022 in Review

Allspring Global Investments sold out of Fulcrum Therapeutics (FULC) in Q4 2022, closing a stake of 9,176 shares — an estimated $74K sold.

Allspring Global Investments first reported a position in FULC in Q4 2021 and held it in 3 quarters. The position peaked at $124K in Q1 2022. 110 funds tracked by Wall St. Rank hold FULC as of Q4 2022.

  • Allspring Global Investments reported no remaining Fulcrum Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Allspring Global Investments sold 9,176 Fulcrum Therapeutics shares in Q4 2022, an estimated $74K.
  • Allspring Global Investments first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 3 quarters.
  • Allspring Global Investments's Fulcrum Therapeutics position peaked at $124K in Q1 2022.
  • 110 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2022.

Based on Allspring Global Investments's 13F filing for Q4 2022, filed 23 Jan 2023.